Total Funding
61
56
Total FundingSeries A raised
Growth Score
-3 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
78311
Stuart Therapeutics is a biotechnology company that offers PolyCol, a therapeutic platform for ophthalmic indications.
- David Calkins: Chief Science Officer
- Eric Schlumpf: Co-Founder, President and CEO
About the Company
Stuart Therapeutics is a biotechnology company that offers PolyCol, a therapeutic platform for ophthalmic indications.
PolyCol’s unique method of action results in accelerated healing and recovery in various ophthalmic disease states and offers a new way to address indications such as dry eye disease, dry age related macular degeneration, and
glaucoma.
PolyCol is based on patented research from a major U.S. university, combined with additional intellectual property acquired by Stuart Therapeutics. The company has developed applications for PolyCol in treating certain ophthalmic, gastrointestinal, inflammatory, and oncology conditions.
